Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
about
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Established and emerging targeted therapies in the myelodysplastic syndromes.Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisLong-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyCurrent therapy of myelodysplastic syndromesClinical utility of lenalidomide in the treatment of myelodysplastic syndromesVariations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletionLenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.Where Does Lenalidomide Fit in Non-del(5q) MDS?Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies.Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).
P2860
Q30235355-13F0A8F1-B79D-4F9E-939C-9078A875A876Q30245476-1BD1DEDF-29E7-4433-9538-1FB8D08EC5BAQ33433453-A682511F-5651-43E1-BD78-0225827CDC38Q33436627-C68227EB-440B-489D-A6BC-7ACBF73EE784Q33675946-3D4AC869-DB26-4C56-80A8-ABB90374D22BQ33914183-DF8F8D0E-5DC5-4FA9-8A47-BA378465BE4CQ34013796-B4A56D14-322E-42C3-BCA3-9299A270A36FQ34783754-35343892-973C-44E3-8081-4275F0DB9FA6Q35638905-24CAF5E4-E189-4FCC-8C70-438B5D94AB08Q37075929-3E3B3041-9214-431F-8284-A6C7DF95128EQ37449333-465DDA6F-F382-4E24-BC56-E598445146A9Q38546273-3B969AD7-D378-470C-82C9-4150558EED7CQ38595266-2CB71131-D8A3-4285-BB72-4B44C31C029AQ38655060-197015CB-1B04-4ED3-9A51-4CA55A08CC86Q38758162-5547D275-E7AB-4EE0-BB40-5C85242083FCQ40420210-590E507C-1C61-4425-9592-1FD73577C351Q48252834-A1362D10-0AA7-4CEC-8D83-DF4E101AAF3EQ50095638-B80A2852-C1F2-47D6-8B6C-361252494938Q50280245-79A316F7-41CE-4A20-B153-314560D0BB1BQ52777531-4E43FDD3-847B-459A-8E0E-64D920D35B79Q53339839-46BC346D-59E8-48BB-B743-982C6E15E9CC
P2860
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Combined treatment with lenali ...... with myelodysplastic syndrome.
@ast
Combined treatment with lenali ...... with myelodysplastic syndrome.
@en
type
label
Combined treatment with lenali ...... with myelodysplastic syndrome.
@ast
Combined treatment with lenali ...... with myelodysplastic syndrome.
@en
prefLabel
Combined treatment with lenali ...... with myelodysplastic syndrome.
@ast
Combined treatment with lenali ...... with myelodysplastic syndrome.
@en
P2093
P1433
P1476
Combined treatment with lenali ...... with myelodysplastic syndrome
@en
P2093
Arlene S Swern
Hussain I Saba
Jeffrey E Lancet
Jennifer Paleveda
Nianhang Chen
Rami S Komrokji
Richard Lush
P304
P356
10.1182/BLOOD-2012-03-415661
P407
P50
P577
2012-08-30T00:00:00Z